RxDoctor Payments Data

Christina Overmann, MD

Neurology · Saint Louis, MONPI 1518527621

Payments from drug & device makers

$1,224in general payments, 2019–2025

Across 100 payments — averaging $12.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$539
  • Pfizer$424
  • Biogen$150
  • Axsome Therapeutics, Inc.$93
  • Genentech USA, Inc.$18

What the payments were for

  • Consulting fees$15012%
  • Food & beverage$1,07488%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie31$539
Pfizer63$424
Biogen1$150
Axsome Therapeutics, Inc.4$93
Genentech USA, Inc.1$18

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,224 in reported general payments places this provider in the 45th percentile of 381 neurology providers in Missouri.

See all neurology providers in Missouri

Medicare billing

Part B allowed, 2024
$172,517
Medicare patients
487
Services billed
5,124

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Nurtec OdtRimegepant Sulfate44$64,070
Aimovig AutoinjectorErenumab-Aooe39$29,280
Tetrabenazine12$23,507
UbrelvyUbrogepant12$19,876
Carbamazepine ErCarbamazepine43$4,215
Levetiracetam116$4,135
Carbidopa-LevodopaCarbidopa/Levodopa174$4,095
Lacosamide52$3,561
DilantinPhenytoin Sodium Extended12$2,232
Gabapentin124$2,187
Primidone57$1,741
Clobazam22$1,385
Memantine Hcl42$1,274
Propranolol Hcl ErPropranolol Hcl46$1,198
Pyridostigmine Bromide11$915

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerNurtec Odt, Dilantin$424$66,30356 claims
AbbVieUbrelvy$539$19,87612 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 381 neurology providers in Missouri.

Other neurology in Saint Louis

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →